Background
==========

*Chlamydia trachomatis*is a highly prevalent sexually transmitted disease \[[@B1]-[@B3]\]. Although there is no systematic screening program in Norway, testing rates among young women are high, as are the positivity rates \[[@B4]\].

By using data from a laboratory that covers all chlamydial diagnostics in a defined geographical area (a Norwegian county), we have previously shown that at the age of 25, one in six women had been diagnosed with *C. trachomatis*at least once \[[@B4]\]. Chlamydial infections have potential long-term consequences such as pelvic inflammatory disease, tubal factor infertility, and ectopic pregnancy \[[@B5]\].

Women with positive test results are often anxious about their future fertility \[[@B6],[@B7]\]. A recent review has however shown that the previously assumed high complication rates of *C. trachomatis*are now being increasingly questioned \[[@B8]\].

We have previously used a registry-linkage approach and applied a retrospective cohort design to investigate ectopic pregnancy rates and birth rates by test result among women tested for *C. trachomatis*in a routine clinical setting \[[@B9]\]. In the present study we have applied a similar design to assess the rate of pelvic inflammatory disease following a diagnosis of *C. trachomatis*.

Methods
=======

The study was carried out in Sør-Trøndelag County, central Norway. Of the county\'s 270,000 inhabitants approximately 150,000 are living in the major city, Trondheim.

Data Sources
------------

In Norway, all citizens are given a unique 11-digit social security number at birth or at immigration. In the current study, we used two databases, both containing the personal identifier and data on residency.

In Sør-Trøndelag County, a single laboratory is responsible for all *C. trachomatis*diagnostics \[[@B4]\]. The *C. trachomatis*database contains information on all tests (date, diagnostic method, and test outcome) in the county from November 1990 to December 2005 with person as the unit of analysis.

Information on all hospitalizations with a diagnosis of pelvic inflammatory disease was obtained from discharge registries 1990--2005 of the two hospitals in the county (Orkdal Hospital and Trondheim University Hospital). Patients with pelvic inflammatory disease were identified through computerized hospital in- and outpatient registries by using the International Classification of Diseases (ICD) 9th Revision code 614 during 1990--98 and the ICD 10th Revision codes N70 over the years 1999--2005.

Laboratory Methods
------------------

Several methods were used for *C. trachomatis*detection throughout the study period\[[@B4]\] Briefly, the IDEIA™ Chlamydia Test, Celltech Diagnostics/Novo BioLabs/DAKO was replaced by PACE 2™, GenProbe in 1992, whereas Amplicor from Roche Molecular Systems became the routine detection method in 1999.

Study Population
----------------

During November 1, 1990, to December 31, 2005, 101,649 women (all ages included) were tested for *C. trachomatis*, among whom 68,807 resided in Sør-Trøndelag County (Figure [1](#F1){ref-type="fig"}). We excluded 1,706 women without a valid personal identifier. In order to obtain a study population with a nearly complete testing history, we limited the population to women who were 20 years old or younger when computerized registration of test results started in 1990. Thus, 42,108 women born before 1970 or after 1984 were excluded from the study population (Figure [1](#F1){ref-type="fig"}). We finally excluded 46 women who were registered with a hospitalization for pelvic inflammatory disease prior to their first registered *C. trachomatis*test. Thus, our study population consisted of 24,947 women who had not experienced a hospitalization for pelvic inflammatory disease prior to their first *C. trachomatis*test.

![**Inclusions and exclusions of women to the study**.](1471-2334-9-130-1){#F1}

Statistical Analysis
--------------------

Confidence intervals (95%) for proportions were calculated using the Wilson method \[[@B10]\]. All other analyses were carried out using SPSS for Windows, version 15.0 (SPSS, Chicago, IL).

For estimation of hazard ratio for pelvic inflammatory disease by *C. trachomatis*status we used Cox regression analysis with months from the first *C. trachomatis*test as the time variable. *C. trachomatis*status was entered as a time-dependent covariate. *C. trachomatis*status changed at the date of a positive test. Analyses were adjusted for age at first test. Women were followed up until the first date of hospitalization with a diagnosis of pelvic inflammatory disease or censored on December 31, 2005.

Ethics
------

The study adheres to the Helsinki Declaration and was approved by the Regional Committee for Research Ethics, Central Norway, and the Norwegian Data Inspectorate. Authorization for the use of laboratory data and data retrieved from medical records was obtained from the Norwegian Directorate of Health and Social Affairs.

Results
=======

The total follow-up time from time of first *C. trachomatis*infection until first hospitalization with a diagnosis of pelvic inflammatory disease or censoring was 201,249 person-years. The average duration of the follow-up period was 8.0 person-years (SD 4.6 person-years).

Testing Pattern
---------------

A total of 93,089 tests were registered among the 24,947 women in our study cohort during the follow-up period. The average age at first test was 21.0 years (SD 3.7). A single test was registered for 6,717 women (27%). Four-thousand-seven-hundred-and-fifty women (19%) were registered with two tests, 3,500 (14%) women had three tests, 2,559 (10%) had four tests, and 7,421 women had five or more tests. There was a large variation in the time intervals between tests. We calculated the time interval between the first two tests and the second and the third test. For 5,408 women, both the time interval between the first two tests and the time interval between the second and the third test were 18 months or shorter, indicating that 22% of the total study population were screened on a fairly regular basis.

Positive tests
--------------

Overall, the proportion of positive tests was 6.0% (5,577/93,089). The proportion of positive tests was highest early in the study period and the prevalence at first test was slightly higher than the total proportion of positive tests (Table [1](#T1){ref-type="table"}).

###### 

Total number of tests, positivity rates, number of first tests, and prevalence at first test among the women in the cohort

                                              1990--93   1994--96   1997--99   2000--03   2004--05
  ------------------------------------------- ---------- ---------- ---------- ---------- ----------
  *All tests*                                                                             
   Total number of tests                      13,134     16,741     18,991     30,020     14,203
   Proportion of positive tests               7.3%       6.2%       5.0%       6.2%       5.6%
  *Restricted to first test for each woman*                                               
   Number of first tests                      6,761      4,588      4,480      6,049      3,069
   Prevalence at first test                   8.0%       7.6%       5.9%       8.2%       7.6%

During the observation period, 18% of the women in the cohort were infected with *C. trachomatis*at least once (4,413/24,947). A single infection was registered for 3,513 women (14%), 701 (3%) were registered with 2 infections, and 199 (1%) with 3 or more infections.

Hospitalizations for PID
------------------------

At least one hospitalization for pelvic inflammatory disease was registered for 191 out of the 24,947 women in the cohort (0.77%).

Forty-eight out of the 4,413 women with prior *C. trachomatis*infection experienced hospitalization with a diagnosis of pelvic inflammatory disease (1.09%; 95% CI, 0.82--1.44). The corresponding number among the 20,534 women without prior infection was 143 (0.70%; 95% CI, 0.59--0.82).

As shown in Table [2](#T2){ref-type="table"}, the incidence rate of hospitalization with a diagnosis of pelvic inflammatory disease was higher for women with one or more prior infections compared to women with negative tests only (hazard ratio, 1.69; 95% CI 1.21--2.37).

###### 

Cox regression analysis of hospitalizations with pelvic inflammatory disease by previous *C. trachomatis*infection

  ------------------------------------------------------------------------------------------------------------------------------------------------
  Prior infections   No. of women\*   Observation years   No. of events   Incidence rate per 100 person-years\   Adjusted† hazard ratio (95% CI)
                                                                          (95% CI)                               
  ------------------ ---------------- ------------------- --------------- -------------------------------------- ---------------------------------
  None               20,534           169,192             143             0.08 (0.07--0.10)                      Reference

  One or more        4,413            32,057              48              0.15 (0.11--0.20)                      1.69 (1.21--2.37)
  ------------------------------------------------------------------------------------------------------------------------------------------------

\* Number of women at end of follow-up period

† Adjusted for age at first test

Discussion
==========

This registry-based cohort study shows that women diagnosed with *C. trachomatis*infection had a slightly higher risk for hospitalization with a diagnosis of pelvic inflammatory disease compared to women with only negative tests.

The present study is unique in that we had access to data on all *C. trachomatis*tests over a long time period (1990--2005) within a well-defined geographic region (county) for a young cohort with a high testing frequency \[[@B4]\], at least compared to previous registry studies \[[@B11],[@B12]\]. By comparison with data from Statistics Norway, we estimate that our population represents approximately 80% of all women born 1970--84 in the study area (data not shown). We identified all cases of pelvic inflammatory disease through hospital in-and outpatient registries.

The study\'s main limitation is that we had no access to data from primary care. Mildly asymptomatic cases treated outside hospital settings or asymptomatic cases are missed. Although such cases also might have potential for long-term adverse reproductive health effects, hospitalizations are likely to reflect the most severe cases of pelvic inflammatory disease. Another limitation of our study is that the study population consists of women tested for *C. trachomatis*in a routine clinical setting. Because the women were not systematically screened, the number of tests for each woman varied, as did the interval between tests. Furthermore, over the study period, there was a change in test technology towards more sensitive tests. Finally, we did not have access to other data of potential interest, such as sexual activity and contraception use.

We found a higher incidence rate of pelvic inflammatory disease among women diagnosed with *C. trachomatis*infection than among women with negative tests only. This result is in concordance with results from a Swedish registry-linkage study \[[@B12]\]. The risk estimate was however slightly lower in that study compared to ours, possibly because we had access to more recent and complete data on both *C. trachomatis*testing and pelvic inflammatory disease hospitalizations (1990--2005 for both exposure and outcome). In the Swedish study, the *C. trachomatis*database covered the time period 1985--1996, while outcomes were assessed until 1999. Missing data on testing history and a large proportion of tests analyzed with less sensitive technology will tend to bias the results towards the null because of misclassification of infection status.

Although the present study showed higher incidence rates of pelvic inflammatory disease among women with prior positive tests than among women with negative tests only, the rates were low in either group. It has been suggested that the relatively low incidence of lower genital tract complications among women diagnosed with *C. trachomatis*infection indicates that the benefits of chlamydia screening programs might have been overestimated \[[@B12]\]. However, the present and previous registry studies include women tested for *C. trachomatis*in routine clinical settings \[[@B9],[@B11]-[@B13]\], and it is most unlikely that a large proportion of women with a diagnosis were left untreated. Thus, the high prevalence rate of infection together with the low incidence rates of complications among women with positive tests might rather indicate that screening for chlamydial infection benefits female reproductive health. Such findings do however show that women with positive test results, often anxious about their future fertility \[[@B6],[@B7]\], can be reassured that the risk of long term reproductive health consequences is low after a treated infection.

Conclusion
==========

The present study shows a clear link between diagnosed *C. trachomatis*infection and subsequent pelvic inflammatory disease. However, hospitalization for pelvic inflammatory disease was a rare event also among women with prior infections. This, held together with previous findings of low ectopic pregnancy rates also among women with prior infection, might indicate that the large-scale opportunistic screening for *C. trachomatis*over the last decades has enhanced the reproductive health of Norwegian women.
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